Exavir Therapeutics Inc Profile last edited on: 3/12/2024
CAGE: 9F4N0
UEI: EV9JGJL7VVF9
Business Identifier: Dedicated to transforming the lives of patients living with or at risk of HIV 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 11
County: San Francisco
Congr. District: 11
County: San Francisco
Public Profile
Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $2,049,976 | |
| Project Title: XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies | ||||
Key People / Management
Alborz Yazdi -- co-founder and CEO
Mark Cockett -- Chief Scientific Advisor
Howard E Gendelman -- co-founder
Janet Gunzner-Toste
Brian Kearney -- Manager
Mark Cockett -- Chief Scientific Advisor
Howard E Gendelman -- co-founder
Janet Gunzner-Toste
Brian Kearney -- Manager
Company News
There are no news available.
